688185.SS实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 15:00):

Stats
今日成交量	1.38M
平均成交量	1.58M
市值	6.29B
EPS	CNY0 ( 2024-04-26 )
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	-8.20
ATR14	CNY0.0490 (0.10%)

音量相关性

長: 0.15 (neutral)

短: -0.04 (neutral)

Signal:(58.337) Neutral

CanSino Biologics Inc. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

CanSino Biologics Inc. 相关性 - 货币/商品

-0.39
( neutral )

-0.58
( weak negative )

0.00
( neutral )

-0.08
( neutral )

-0.10
( neutral )

-0.47
( neutral )

CanSino Biologics Inc. 财务报表

Annual	2023
营收:	CNY349.12M
毛利润:	CNY-21.83M (-6.25 %)
EPS:	CNY-6.01

FY	2023
营收:	CNY349.12M
毛利润:	CNY-21.83M (-6.25 %)
EPS:	CNY-6.01

FY	2022
营收:	CNY1.03B
毛利润:	CNY-186.61M (-18.10 %)
EPS:	CNY-3.91

FY	2021
营收:	CNY4.30B
毛利润:	CNY3.00B (69.85 %)
EPS:	CNY7.74

Financial Reports:

No articles found.

CanSino Biologics Inc.

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.